600488 津药药业
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入863,770-12.80%3,782,8273,688,9303,748,6653,116,848
减:营业总成本759,001-12.41%3,590,1763,485,9793,566,7212,951,809
    其中:营业成本475,5145.60%2,026,6431,878,6681,963,0271,682,910
               财务费用3,461-72.54%17,21129,24845,23544,358
               资产减值损失(32,754)8.62%(57,226)(123,935)(53,351)(45,103)
公允价值变动收益0-100.00%--------
投资收益786-129.32%(1,126)(22,437)4,985(1,221)
    其中:对联营企业和合营企业的投资收益782-129.74%(266)(1,952)1,615(1,221)
营业利润78,200-16.50%169,40770,208145,834132,421
利润总额79,617-15.06%168,24012,517149,067112,380
减:所得税费用7,1351.28%5,567(5,920)40,40031,805
净利润72,483-16.38%162,67318,437108,66880,575
减:非控股权益14,470-24.65%45,621(16,969)60,00046,596
股东净利润58,012-14.03%117,05335,40648,66833,979

市场价值指针
每股收益 (元) *0.053-14.52%0.1070.0320.0450.031
每股派息 (元) *----0.0870.0100.0140.010
每股净资产 (元) *2.754-0.75%2.7002.7112.7212.718
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容